On November 11, GENSCRIPT B-1K fell 3.61% in Regular Trading, trading at HK$33.4, with turnover of HK$17.54 million.
The latest identifiable catalyst was the company’s announcement that associate Legend Biotech had released its third-quarter financial results and recent business updates, after which market sentiment appeared to turn more mixed.
Company disclosures stated that the released figures relate only to Legend Biotech and do not reflect GENSCRIPT B-1K’s own financial results or operating performance. This matters because recent strength in the stock had been tied mainly to AIDD-driven wet-lab demand, broker optimism, and upgraded profit expectations, while the new disclosure shifted attention toward the associate’s update and introduced near-term sentiment divergence.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments